Full text is available at the source.
Abstract
mRNA cancer vaccines may enhance personalized immunotherapy by delivering tumor-associated or tumor-specific neoantigens.
- mRNA cancer vaccines are designed to stimulate a strong immune response against specific cancer cells.
- Emerging clinical trial data indicates potential effectiveness across various solid tumors.
- Current limitations of mRNA vaccines in cancer treatment include challenges in patient selection and response variability.
- Future clinical trials should prioritize combination treatments to improve the immune response against tumors.
- Adaptive trial designs may help speed up the clinical application of mRNA cancer vaccines.
Simplified